二甲双胍治疗2型糖尿病的药物基因组学研究进展

发布时间：2018-04-19 05:40

本文选题：二甲双胍 + 糖尿病　；参考：《中国糖尿病杂志》2017年08期

【摘要】：二甲双胍作为糖尿病一线治疗用药,使用广泛。但在实际临床使用中,二甲双胍的疗效和不良反应均存在个体差异,这可能与患者的遗传背景有关。研究参与二甲双胍的吸收、转运、摄取、排泄过程的相关基因多态性,与药物代谢和疗效多样性之间关系的药物基因组学,成为目前研究的热点。药物基因组学也是精准医学的理论基础之一。本文就二甲双胍治疗T2DM的药物基因组学研究进展进行文献综述。
[Abstract]:Metformin is widely used as a first-line treatment for diabetes.However, there are individual differences in the efficacy and adverse reactions of metformin in clinical use, which may be related to the genetic background of the patients.The study of the genetic polymorphism involved in metformin absorption, transport, uptake and excretion, and its relationship with drug metabolism and therapeutic diversity, has become a hot topic.Pharmacogenomics is also one of the theoretical bases of precision medicine.This article reviews the advances in pharmacogenomics of metformin in the treatment of T2DM.
【作者单位】：北京大学人民医院内分泌科;
【分类号】：R587.1

【相似文献】